Fully integrated pharma manufacturer of bulk APIs/intermediates and finished-dosage formulations, among the largest producers/exporters of Gliclazide, with herbal (Bal Vedics) and institutional product lines
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 14 | 15 | 15 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 38 | 39 | 44 | 48 | 56 | 62 | 62 | 66 |
| Borrowings | 118 | 110 | 104 | 131 | 140 | 150 | 155 | 160 |
| Other Liabilities | 68 | 76 | 98 | 116 | 108 | 108 | 116 | 134 |
| Total Liabilities | 238 | 240 | 261 | 311 | 320 | 336 | 349 | 376 |
| AssetsFixed Assets | 71 | 69 | 67 | 76 | 80 | 87 | 92 | 94 |
| CWIP | 3 | 0 | 2 | 0 | 0 | 3 | 3 | 7 |
| Investments | 0 | 0 | 0 | 0 | 7 | 2 | 0 | 2 |
| Other Assets | 164 | 172 | 192 | 235 | 233 | 244 | 253 | 272 |
| Total Assets | 238 | 240 | 261 | 311 | 320 | 336 | 349 | 376 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 8 | 23 | 22 | 27 | -2 | 23 | 20 | 30 |
| Cash from Investing | -8 | -5 | -6 | -9 | -22 | -19 | -15 | -21 |
| Cash from Financing | 0 | -20 | -17 | -17 | 24 | -1 | -8 | -10 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -1 | 18 | 19 | 18 | -16 | 12 | 2 | 8 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
BALPHARMA · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.